CCR2 and type 2 diabetes mellitus: As summarized in the present review, there might be a potential therapeutic value of targeting certain immune resident cells (such as M2, Tregs, or MDSC) and/or certain cytokines, adipokines, or chemokines (such as MCP-1/CCR2 or CCR5) to improve insulin resistance and restrain organ damage in type 2 diabetic obese patients by limiting the proinflammatory milieu.